MingJu Therapeutics Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2017
NCT03344367
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

MingJu Therapeutics (Shanghai) Co., Ltd

Active Ingredients

Drugs in Phase 1 Trials (1)

cd19 car-t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1